Complete enrollment of the third cohort of the U.S. Phase I/II study
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Jul 2024
- Due
- 31 Dec 2024
- Delivered
- February 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“In the second half of 2024, uniQure expects to complete enrollment of the third cohort of the U.S. Phase I/II study exploring AMT-130 in combination with immunosuppression.”
What we found
Evidence strength A What the grades mean
The company completed enrollment of the third cohort in February 2025, which occurred after the stated deadline of the second half of 2024.
-
A uniQure N.V. 8-K filed 2025-02-27
“In February 2025, the Company completed enrollment of all 12 patients in the third cohort investigating an optimized immunosuppression regimen.” ✓ confirmed on the page
Market reaction: the shares moved -4.8% against the S&P 500 over the three sessions around the disclosure (26 Feb 2025 to 3 Mar 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Enrollment of the third cohort of the U.S. Phase I/II study
- Where
- U.S.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-QURE-001876 · Corrections policy